Avanos appoints David Pacitti as CEO, effective April 14, 2025; compensation disclosed

AVANOS MEDICAL, INC.

David Pacitti, former Siemens Healthineers Americas President, becomes CEO effective April 14, 2025.
Compensation: $1.05M base salary, 110% bonus target, $5M annual LTI target for 2026.
One-time equity awards: $3.5M PRSUs (stock price hurdles $20-$33) and $3.5M TRSUs (3-year vest).
Receives $500K cash sign-on; also serves on Orchestra BioMed (OBIO) board since March 2024.
Interim CEO Michael Greiner to continue until Pacitti starts.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David Pacitti

Chief Executive Officer

AVNS · AVANOS MEDICAL, INC.

Effective: 2025-04-14
Filed: April 18, 2025, 7:59 PM ET

On March 17, 2025, Avanos Medical, Inc. (the “Company”) announced the appointment of David Pacitti as the Company’s Chief Executive Officer, effective April 14, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Pacitti was appointed as Chief Executive Officer at AVANOS MEDICAL, INC..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On March 17, 2025, Avanos Medical, Inc. (the “Company”) announced the appointment of David Pacitti as the Company’s Chief Executive Officer, effective April 14, 2025.

View on SEC.gov

AVANOS MEDICAL, INC. filing history →

Source: SEC EDGAR

accession 0001606498-25-000063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.